Douglas J. Jolly - Leucadia CA Stephen Chang - Poway CA James G. Respess - Pacific Beach CA Nicholas J. DePolo - Solano Beach CA David Chi-Tang Hsu - San Diego CA Carlos E. Ibanez - San Diego CA Judith Greengard - San Diego CA Lee Will - Carlsbad CA
Methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the step of administering to a human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 10 cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of the human.
Douglas Jolly - Leucadia CA, US Stephen Chang - Poway CA, US William Lee - Carlsbad CA, US Kay Townsend - Encinitas CA, US Joanne O'Dea - La Jolla CA, US
International Classification:
A61K048/00 A61K039/29
US Classification:
424/093200, 424/189100, 514/044000
Abstract:
The present invention provides methods of treating hepatitis C infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of a hepatitis C antigen, such that an immune response is generated. Also provided are vector constructs which direct the expression of at least one portion of a hepatitis C antigen, as well as recombinant viruses which carry such vector constructs.
Jack Barber - San Diego CA, US Douglas Jolly - La Jolla CA, US James Respess - San Diego CA, US Stephen Chang - San Diego CA, US
International Classification:
C12Q001/70 C12N007/00 C12N005/08
US Classification:
435/235100, 435/366000, 435/005000
Abstract:
The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titer than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.
Jack Barber - San Diego CA, US Douglas Jolly - La Jolla CA, US James Respess - San Diego CA, US Stephen Chang - San Diego CA, US
International Classification:
C12N005/08 C12P021/00 C12N007/00
US Classification:
800/004000, 435/366000, 435/235100
Abstract:
The invention described herein allows the production of recombinant retroviruses (retroviral vector particles) from producer cells which are safer and of higher titre than normal. In addition, methods are provided for making helper cells which, when a recombinant retrovirus genome is introduced to make a producer line, produce particles that are targeted toward particular cell types. Methods are also provided for making recombinant retrovirus systems adapted to infect a particular cell type, such as a tumor, by binding the retrovirus or recombinant retrovirus in the particular cell type. Methods are also provided for producing recombinant retroviruses which integrate in a specific small number of places in the host genome, and for producing recombinant retroviruses from transgenic animals.
Thomas Dubensky - Rancho Sante Fe CA, US John Polo - San Diego CA, US Carlos Ibanez - San Diego CA, US Stephen Chang - San Diego CA, US Douglas Jolly - Leucadia CA, US David Driver - San Diego CA, US Barbara Belli - San Diego CA, US
The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
Thomas Dubensky - Rancho Sante Fe CA, US John Polo - San Diego CA, US Carlos Ibanez - San Diego CA, US Stephen Chang - San Diego CA, US Douglas Jolly - Leucadia CA, US David Driver - San Diego CA, US Barbara Belli - San Diego CA, US
Assignee:
Chiron Corporation
International Classification:
C12N015/861 C12N015/86
US Classification:
435/456000, 435/320100, 435/325000
Abstract:
The present invention provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems.
John M. Polo - San Diego CA, US Carlos E. Ibanez - San Diego CA, US Stephen M.W. Chang - San Diego CA, US Douglas J. Jolly - Leucadia CA, US David A. Driver - San Diego CA, US Barbara A. Belli - San Diego CA, US
International Classification:
C12N 5/071
US Classification:
435375
Abstract:
The present disclosure provides compositions and methods for utilizing recombinant alphavirus vectors. Also disclosed are compositions and methods for making and utilizing eukaryotic layered vector initiation systems
Automated System For Producing Induced Pluripotent Stem Cells Or Differentiated Cells
New York Stem Cell Foundation - , US Kevin C. Eggan - Boston MA, US Stephen Chang - Poway CA, US Susan Solomon - New York NY, US
Assignee:
New York Stem Cell Foundation - New York NY
International Classification:
C12N 5/074
US Classification:
506 14, 4352851, 4353051, 435377, 4352871
Abstract:
The invention provides an automated system for producing induced pluripotent stem cells (iPSCs) from adult somatic cells. Further, the system is used for producing differentiated adult cells from stem cells. The invention system is useful for isolating somatic cells from tissue samples, producing iPSC lines from adult differentiated cells by reprogramming such cells, identifying the pluripotent reprogrammed adult cells among other cells, and expanding and screening the identified reprogrammed cells.
Name / Title
Company / Classification
Phones & Addresses
Stephen Chang Sales Executive
Canji Inc Commercial Physical and Biological Research
3525 John Hopkins Ct, San Diego, CA 92121
Stephen Chang CEO
Xenogenics Corporation Research & Development in Biotechnology
701 George Washington Hwy, Lincoln, RI 02865 4017620045, 4013330659
Stephen Chang Chief Executive Officer President Director
Multicell Technologies, Inc Cell Development and Research Activities · Pharmaceutical Preparations
68 Cumberland St, Woonsocket, RI 02895 4017620045
Stephen Chang Sales Executive
Canji, Inc Noncommercial Research Organization · Commercial Physical Research · Laboratories-Research & Develo · Noncommercial Research Organizations
3525 John Hopkins Ct, San Diego, CA 92121 8585970237, 6195970177, 8585970177
With 16.9 million voters registered statewide, more than 4 million Texas, or about 24%, cast a ballot in the first week of early voting, according to Stephen Chang, communications director for the Texas Secretary of State.
Spring Hill Elementary School Mclean VA 1985-1988, Haycock Elementary School Falls Church VA 1988-1992, Longfellow Middle School Falls Church VA 1992-1994
Community:
Bill Adler, Tina Culp, Becky Griese, Dwight Kiser, Carrie Bailey
Forest Ridge Elementary School Laurel MD 1994-2000, Murray Hill Middle School Laurel MD 2000-2003, Patuxent Valley Middle School Jessup MD 2000-2003, Reservoir High School Fulton MD 2003-2007
Sony Pictures Television - Senior Financial Analyst (2010) The Walt Disney Company - Financial Analyst (2008-2010) Countrywide Financial - Senior Financial Specialist (2006-2008)
Education:
Loyola Marymount University - Finance, Asian Studies
Stephen Chang
Work:
Washington Hospital Center - Research Associate Georgetown University Medical Center - Research Associate